Did the FDA just open the door for Commercial to discuss off-label data?

The door opened in January 2025. Most of the industry is still standing in front of it.

Last year, the FDA finalized its SIUU guidance — Scientific Information on Unapproved Use(s) of approved or cleared medical products. For years, the rule most of us were trained on was simple:

SIUU complicates that.

The final guidance doesn't permit off-label promotion. It doesn't erase the line between Medical and Commercial. It doesn't remove the need for Legal, Regulatory, Compliance, or Medical review.

But it does make one major change clear: The framework is not limited to Medical Affairs.In practice, this means appropriately trained sales or marketing personnel may be able to share certain SIUU materials, but only if the communication remains truthful, non-misleading, scientifically sound, properly contextualized, separated from promotion, and supported by the right disclosures.

At the October 2025 Pharmaceutical and Medical Device Ethics and Compliance Congress — 10 months after the guidance finalized — practitioners were polled on who in their organization may disseminate off-label scientific information. For third-party source documents:

→ 58% still restrict it to Medical Affairs
→ 29% permit Commercial
→ 13% disseminate nothing off-label at all

The guidance names no such departmental restriction. The gate isn't the department. It's the capability: the ability to share truthful, non-misleading scientific information, separate it from promotion, preserve scientific integrity, and handle the follow-up question.

So read the gap closely. The door opened, and the most SIUU-aware room in the industry — compliance professionals, the people who read the guidance line by line — looked at it and mostly defaulted to the old rule. Not because the old rule still applies the same way. Because most organizations haven't built the system to do anything else.

That's the real story of SIUU. Not the rule change. The paralysis after it.

And the paralysis matters more than the rule, because a risk-averse default feels safe while quietly making a decision no one actually made.

When an organization reverts to "Medical Affairs handles all off-label" in the absence of a deliberate framework, it isn't choosing caution. It's letting the absence of a decision become the decision. Defaults that harden in a vacuum don't get revisited — they become "how we've always done it," long before anyone notices they were never designed.

That's where this stops being a compliance footnote and starts shaping field engagement, for better or worse.

We know the field model is already crowded. In a single territory, an HCP may interact with MSLs, clinical educators, field reimbursement managers, thought leader liaisons, market access teams, patient support roles, account teams, sales representatives. Some sit in Medical, some in Commercial, some closer to access or education.

From the HCP’s point of view, many of them look similar: field-based, external-facing, calling on the same accounts, around the same disease state, although they aren't solving the same problem.

SIUU widened who may carry certain scientific information about an unapproved use into that crowded field. But it gated the privilege on a capability many of those roles were never hired, trained, or measured for: the judgment to tell the difference between sharing science and selling a use, in real time, with a customer waiting.

Take the clinical educator. They sit in Commercial, but they're neither sales nor marketing — which is exactly the problem. The guidance named sales and marketing personnel. It didn't say a word about clinical educators. So under SIUU, a clinical educator could in principle share qualifying off-label scientific information, but they fall into a category the guidance never explicitly addressed, and most organizations haven't decided whether that door is open, closed, or conditional for that role.

But many clinical educators were never hired for scientific exchange under regulatory scrutiny. They were hired to educate within approved-use boundaries. The guidance opened a door their job description may never have accounted for.

That undecided space is where field engagement gets reshaped. The question is no longer simply: "Can Commercial talk about off-label?"

It's:

When roles multiply and the communication architecture stays undefined, the organization doesn't become more capable. It becomes more exposed. Not because people are careless. Because the system never specified who owns what.

The common read is that all of this diminishes Medical Affairs. If Commercial can share science too, Medical's hold on science erodes. I beg to differ. If anything, it’s the opposite.

Think about:

These aren't checklist questions. They require judgment, and someone has to set the standard for that judgment across every customer-facing role, not just their own.

That's a larger role than Medical Affairs has historically held. It's also a closing window, because the defaults are hardening right now. The 58% reverting to "Medical handles it" aren't necessarily choosing Medical Affairs leadership. They may be choosing Medical Affairs as the path of least resistance — a place to park risk until someone decides otherwise.

That's leadership by accident, and it's fragile.

The moment Commercial pushes — and under a more permissive framework, Commercial has every incentive to push — a default that was never designed has nothing to defend it.

The organizations that get this right will treat the current paralysis as the opening, not the answer. They'll define the architecture deliberately who shares, under what training, reviewed by whom, documented how, routed where, monitored against what standard, before the vacuum fills itself.

AI makes SIUU more urgent because HCP behavior has already changed.

HCPs are not waiting for pharma to bring them information. They are already accessing off-label data through publications, congress coverage, online medical communities, search, social platforms, and AI-generated summaries.

That changes the role of the field. The question is no longer whether information on unapproved uses exists in the ecosystem. It does. The question is whether company representatives are prepared to respond with scientific integrity when HCPs bring that information into the conversation.

SIUU did not create this reality. It forces companies to deal with it.

A rigid “we cannot discuss that” may protect the company in one sense. But if the only next step is to ask the HCP to fill out a form, wait for a follow-up, or schedule a separate call, the process itself can become a bottleneck.

In oncology, practice often moves faster than the label — a dose adjustment, treatment sequence, or biomarker-defined use may be in the literature and in practice before the label catches up. That doesn't make it promotional, and it doesn't make it appropriate for any field role to discuss. But if an oncologist is already asking about data they've seen, a delayed handoff protects the company procedurally while leaving the HCP without timely scientific context.

That is the tension SIUU exposes. Not because every field role should discuss off-label data. But because companies now have to decide, deliberately, how scientific information should move when HCPs are already moving faster than the internal process.

SIUU didn't erase the line between Medical and Commercial. It made the line harder to see and more important to hold. The companies that handle it well won't be the ones asking: Can we share this?

They'll be the ones who already answered: Do our people understand what this means, where the boundaries are, and how to communicate science without compromising credibility?

The door is open. The paralysis is real.

And right now, in much of the industry, the absence of a decision is making the decision.

That's not just a compliance problem. It's a leadership one.

P.S. Most organizations can't yet answer a simple question: which roles on their field roster are actually equipped to carry scientific information about an unapproved use — and which are one gray-zone follow-up away from exposure. That's the gap I help Medical Affairs leaders map before the default hardens into policy no one chose. If that's the conversation your team needs to have, reach me directly at [email protected].

References